NCOA6 Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a partial recombinant NCOA6.
|Application ||WB, IF|
|Calculated MW||219145 Da|
|Other Names||Nuclear receptor coactivator 6, Activating signal cointegrator 2, ASC-2, Amplified in breast cancer protein 3, Cancer-amplified transcriptional coactivator ASC-2, Nuclear receptor coactivator RAP250, NRC RAP250, Nuclear receptor-activating protein, 250 kDa, Peroxisome proliferator-activated receptor-interacting protein, PPAR-interacting protein, PRIP, Thyroid hormone receptor-binding protein, NCOA6, AIB3, KIAA0181, RAP250, TRBP|
|Target/Specificity||NCOA6 (NP_054790, 1954 a.a. ~ 2063 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.|
|Format||Clear, colorless solution in phosphate buffered saline, pH 7.2 .|
|Storage||Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.|
|Precautions||NCOA6 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The protein encoded by this gene is a transcriptional coactivator that can interact with nuclear hormone receptors to enhance their transcriptional activator functions. The encoded protein has been shown to be involved in the hormone-dependent coactivation of several receptors, including prostanoid, retinoid, vitamin D3, thyroid hormone, and steroid receptors. The encoded protein may also act as a general coactivator since it has been shown to interact with some basal transcription factors, histone acetyltransferases, and methyltransferases.
Association of a common AGO1 variant with lung cancer risk: A two-stage case-control study. Kim JS, et al. Mol Carcinog, 2010 Oct. PMID 20721975.Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. Rose JE, et al. Mol Med, 2010 Jul-Aug. PMID 20379614.ASCOM controls farnesoid X receptor transactivation through its associated histone H3 lysine 4 methyltransferase activity. Kim DH, et al. Mol Endocrinol, 2009 Oct. PMID 19556342.PRIP promotes tumor formation through enhancing serum-responsive factor-mediated FOS expression. Zhu YT, et al. J Biol Chem, 2009 May 22. PMID 19329434.Multiple genetic variants along candidate pathways influence plasma high-density lipoprotein cholesterol concentrations. Lu Y, et al. J Lipid Res, 2008 Dec. PMID 18660489.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.